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Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an exceedingly rare disorder categorized under acute
myeloid leukemia by the World Health Organization. Phenotypically, malignant cells coexpress CD4þ and
CD56þ without coexpressing common lymphoid or myeloid lineage markers. BPDCN frequently expresses
CD123, TCL1, BDCA-2, and CD2AP. Restriction of CD2AP expression to plasmacytoid dendritic cells makes it
a useful tool to help conﬁrm diagnosis. Clonal complex chromosome aberrations are described in two-thirds
of cases. Eighty percent of BPDCN cases present with nonspeciﬁc dermatological manifestations, prompting
inclusion in the differential diagnosis of atypical skin rashes refractory to standard treatment. Prognosis is
poor, with a median survival of less than 18 months. No prospective randomized data exist to deﬁne the most
optimal frontline chemotherapy. Current practice considers acute myeloid leukemia-like or acute lympho-
blastic leukemiaelike regimens acceptable for induction treatment. Unfortunately, responses are short-lived,
with second remissions difﬁcult to achieve, underscoring the need to consider hematopoietic cell trans-
plantation early in the disease course. Allografting, especially if offered in ﬁrst remission, can result in long-
term remissions. Preclinical data suggest a potential role for immunomodulatory agents in BPCDN. However,
further research efforts are needed to better understand BPDCN biology and to establish evidence-based
treatment algorithms that might ultimately improve overall prognosis of this disease.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION LITERATURE SEARCH
Blastic plasmacytoid dendritic cell neoplasm (BPDCN),
previously known as blastic natural killer (NK) cell lym-
phoma or CD4þ/CD56þ hematodermic neoplasm, is an
exceedingly rare hematological disorder currently catego-
rized under acute myeloid leukemia (AML) and related
precursor neoplasms in the 2008 World Health Organization
classiﬁcation [1-4]. Limited amounts of literature are avail-
able on BPDCN for disease biology and treatment options.
There is no established standard of care for BPDCN, and the
prognosis remains generally poor with a median survival
of typically less than 18 months using conventional chemo-
therapy regimens [5,6]. Hematopoietic cell transplantation
(HCT) appears to be an attractive treatment option for
patients with BPDCN, although experience is mostly anec-
dotal, supported by small case series.
Here, we provide a comprehensive review of BPDCN.
We summarize the published medical literature regarding
disease biology and treatment outcomes after conventional
chemotherapy and HCT, autologous or allogeneic. We
also present suggested treatment strategies and explore
future therapeutic options.edgments on page 1011.
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13.01.027A comprehensive literature search was performed using
PubMed (1966 to November 30, 2012), with the following
search strategy: ((“Dendritic Cells”[Mesh] AND “Antigen-
Presenting Cells”[Mesh]) AND “Neoplasms”[Mesh]) AND
“Leukemia”[Mesh]. We identiﬁed 677 publications (not
relevant to BPDCN ¼ 437, relevant to BPDCN ¼ 240).
Clinical, Morphological, Biological, and Genetic
Characteristics
BPCDN represents 0.27% of cases presenting as non-
Hodgkin lymphoma and 0.76% of cases presenting as AML in
theWesternhemisphere [7]. A Japanese study reported a 6.3%
incidence among NK cell lineage neoplasms [8]. Median age
at presentationwas 60 to 70 years with amale predominance
(3:1) [9]. BPDCN has also been described in children and
younger adults, who appear to have a less aggressive
clinical course [10]. The disease has a proclivity to involve
the skin, bone marrow, and lymph nodes [2,11]. Organo-
megaly is also frequently described [1]. More than 80% of
cases present with skin lesions without speciﬁc morpholog-
ical features or pattern of distribution and are often asymp-
tomatic or might be associated with pain and pruritus [2,11].
Typically, the malignant cell in BPDCN has abundant
cytoplasm with a medium or low nucleus-to-cytoplasmic
ratio and displays faint basophilia without granulation.
However, microvacuoles are commonly seen, most likely
made of glycogen, arranged in a way to adopt a “pearlTransplantation.
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characteristic pseudopod-like cytoplasmic expansions [2].
Malignant cells of BPDCN generally coexpress CD4þ and
CD56þ without coexpressing common lymphoid or myeloid
lineage markers (Figure 1A, B, C) [1,10,12]. Garnache-Ottou
et al. demonstrated, however, that some cases of BPDCN
express myeloid markers (CD33), suggesting that CD33
expression on CD4þCD56þ cells should not exclude such
diagnoses [12]. Differential diagnosis of CD4þCD56þ malig-
nancy includes aggressive NK cell lymphoma/leukemia,
nasal and nasal-type NK cell lymphoma, and AML (especially
cases with aberrant expression of CD4 and/or CD56 and
cutaneous involvement) [13]. Several cases of BPDCN
showed coexpression of CD2, CD7, CD33, and/or CD117 [9,12].
Identiﬁed key markers include CD123, the interleukin-3
receptor a-chain, T cell leukemia/lymphoma 1 (TCL1),
blood dendritic cell antigen-2 (CD303/BDCA-2), and CD2-
associated protein (CD2AP) [1,3,4,10]. CD2AP is an 80-kDa
molecule identiﬁed through its binding to the terminal
20 amino acids in the cytoplasmic domain of the
T celleassociated molecule CD2 [14]. CD2AP appears to be
restricted to plasmacytoid dendritic cells, potentially making
it a useful tool to conﬁrm the diagnosis of BPDCN [15].
Clonal, generally complex, chromosome aberrations have
been described in 66% of cases [16]. Leroux et al. deﬁned 6
major recurrent chromosomal targets, 5q, 12p, 13q, 6q, 15q,
and monosomy 9, implicated in 72% (5q), 64% (12p and 13q),
50% (6q), 43% (15q), and 28% (monosomy 9) of cases [16].
Lucioni et al. demonstrated that complete or partial chro-
mosomal losses are more frequent than gains, with common
deleted regions including 9p21.3 (CDKN2A/CDKN2B),
13q13.1-q14.3 (RB1), 12p13.2-p13.1 (CDKN1B), 13q11-q12Figure 1. (A) Punch biopsy of a skin lesion in a patient with BPDCN showing a strikin
scant cytoplasm throughout the papillary and superﬁcial reticular dermis (H&E stainin
on malignant cells. (Parts A and B reproduced from Hamadani M, Magro CM, Porcu P.
Haematol 2008;140:122, with permission from John Wiley and Sons [license numb(LATS2), and 7p12.2 (IKZF1) [17]. Worse outcomes were
apparently described in the presence of biallelic loss of locus
9p21.3 [17].
Conventional Therapy
Because of the rarity of BPDCN, no prospective data are
available to deﬁne the most optimal frontline therapy.
Limited cutaneous disease at presentation, without obvious
nodal, bone marrow, and/or peripheral blood involvement,
is not uncommon. However, even in such cases, local thera-
pies (eg, surgical excision or involved ﬁeld radiation therapy)
are ineffective, with systemic relapse anticipated in almost
all cases, typically within 6 months [18].
Frontline treatment with regimens commonly used in
non-Hodgkin lymphoma (eg, cyclophosphamide, doxoru-
bicin, vincristine, prednisone [CHOP]; CHOP-like regimens;
or ifosfamide/etoposide-based regimens) yield complete
remission (CR) rates of 40% to 50%, but responses are short-
lived [2,13,18]. Recent literature, albeit limited by small
sample size, describedmore intense regimens, such as hyper-
CVAD (hyperfractionated cyclophosphamide, vincristine,
doxorubicin, dexamethasone alternating with methotrexate
and cytarabine), offered as frontline therapy for BPDCN with
more encouraging responses [19]. Pemmaraju et al. reported
a CR rate of 90% in 10 patients, with a median age of 62 years
(range, 20 to 86), treated with hyper-CVAD. However,
responses were relatively short-lived at a median of 20
months (range, 4 to 39), andmedian overall survival (OS) was
29 months (range, 1 to 44) [19].
Dietrich et al. reported a CR rate of 83% in 6 patients
treated with daunorubicin plus cytarabine followed by
high-dose cytarabine (AML-like, n ¼ 3) or an acuteg diffuse inﬁltrate of atypical mononuclear cells with round to oval nuclei and
g). Immunohistochemical staining showing expression of CD4 (B) and CD56 (C)
CD4þ CD56þ hematodermic tumor [plasmacytoid dendritic cell neoplasm]. Br J
er: 3034330839698]. All rights reserved.)
Table 1
Selected Published Data Evaluating Conventional Chemotherapy for BPDCN (with at Least 4 Cases)
Author Publication
Year
n (Gender) Median Age
(Range) yr
Chemotherapy
Regimen
Responses Outcomes
Reimer
et al. [13]
2003 83* d (1) Acute leukemiaelike (n ¼ 17), (2) NHL-like
(n ¼ 38), (3) less than CHOP-regimen (n ¼ 28)
CR rates: (1) 94%,
(2) 55%, (3) 68%
Median OS: (1) 13 mo, (2) 13 mo, (3) 9 mo CR
at last follow-up 35% in (1)
Bueno et al. [7] 2004 5 (M ¼ 4) 63 (52-80) Various (CHOP; IDAþcytarabine; cytarabineþ
thioguanine; daunorubicinþcytarabine;
vincristineþdaunorubicinþprednisone
CR1 ¼ 4
PR1 ¼ 1
Two relapsed, median DFS 6 mo (range, 0 to 54), 4 died,
median OS 10 mo (range, 2 to 54)
Dalle et al. [18] 2010 39 (M ¼ 26) 70 (8-94) NHL-like (n ¼ 23), AML-like (n ¼ 6), ALL-like
(n ¼ 3), others regimens (n ¼ 7)y
CR1 ¼ 19
PR1 ¼ 9
PD ¼ 11
Median RFS 6 mo (range, 2 to 42), 18 received salvage therapy,
1 received auto-HCT, 9 received allo-HCT
Tsagarakis
et al. [11]
2010 19 (M ¼ 13) 73 (17-83) ALL-like (n ¼ 9), AML-like (n ¼ 6), NHL-like
regimen (n ¼ 4)
CR1 ¼ 15
(78.9%)
Six (40%) relapsed, 5 (26.3%) received allo-HCT
Dietrich
et al. [20]
2011 6 (M ¼ 4) 68 (55-80) ALL-like (n ¼ 3), AML-like (n ¼ 2), CHOP14 CR1 ¼ 5
PR1 ¼ 1
Median TTR 7 mo (range, 3 to 11)
Received allo-HCT in CR1 (n ¼ 1), in PD (n ¼ 2),
and after salvage therapy with high-dose methotrexate
(8 g/m2)-based regimen (n ¼ 2)
Lucioni
et al. [17]
2011 15 (M ¼ 10) 64 (9-84) ALL-like (n ¼ 9), NHL-like (n ¼ 4), others
regimens (n ¼ 2)
CR1 ¼ 9
PR1 ¼ 6
Ten relapsed, median TTR 9 mo (range, 4 to 36), 9 died,
5 alive and disease free, 2 alive with disease,
median survival 13 mo (range, 8 to 72), 2 received HCT
after relapse
Borchiellini
et al. [42]
2012 4 (M ¼ 1) 69 (50-79) NHL-like (n ¼ 2), AML-like (n ¼ 1), other
regimens (n ¼ 1)
CR1 ¼ 2
SD ¼ 2
All 4 relapsed, one received allo-HCT
An et al. [43] 2012 6 (M ¼ 3) 34 (18-62) CHOP (n ¼ 2), VPDL (n ¼ 2), daunorubicinþ
cytarabine (n ¼ 1), VAD (n ¼ 1)
CR1 ¼ 3
PD ¼ 3
Alive in CR (n ¼ 3), PFS ranges from 2.6 to 28.9 mo,
OS ranges 4.4 to 31.2 mo
One received auto-HCT
Pagano
et al. [36]
2012 41 d AML-like (n ¼ 26), ALL/lymphoma-like
regimen (n ¼ 15)
CR1 ¼ 17
(41%)
PR1 ¼ 6
Resistant ¼ 11
Six of 17 CR relapsed, 7 died during induction, median OS
8.7 mo (range, 0.2 to 32.9), 6 received allo-HCT
Summary of
listed studies
2003-2012 218 Median age
6th decade
of life
AML- or ALL-like (n ¼ 98), NHL-like (n ¼ 104),
miscellaneous or unknown (n ¼ 16)
CR with AML/ALL-like
regimens around 80%-90%,
with NHL-like regimens
w40%-50%
Median OS generally 12 to 18 mo in most listed studies
d indicates not reported/not speciﬁed;M,male; ALL, acute lymphoblastic leukemia; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR1, ﬁrst complete remission; IDA, idarubicin; NHL, non-Hodgkin lymphoma;
PD, progressive disease; PR1, ﬁrst partial response; SD, stable disease; VAD, vincristine, doxorubicin, dexamethasone; VPDL, vincristine, methylprednisolone, daunorubicin, L-asparaginase; TTR, time to relapse.
* Represents compiled case reports from various publications (summarized by Reimer et al. [13]).
y Chemotherapy regimens are summarized in the table by Dalle et al. [18].
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dexamethasone, methotrexate, vincristine, cyclophospha-
mide/ifosfamide, and idarubicin/daunorubicin (n ¼ 3) [20].
Unfortunately, the median time-to-disease relapse was only
7 months (range, 3 to 11) from start of induction therapy;
four cases were able to proceed with allogeneic HCT
(allo-HCT).
These ﬁndings suggest that conventional chemotherapy
does not appear to be sufﬁcient by itself to ensure durable
long-term remissions. The potential role of maintenance
therapy warrants investigation in BPDCN. Table 1 summa-
rizes outcomes using various conventional chemotherapy
regimens that include at least 4 patients [21-34].
Hematopoietic Cell Transplantation
There are no published randomized controlled trials
evaluating the role of autologous HCT (auto-HCT) or allo-HCT
in patients with BPDCN. Most data are limited to small case
series or single case reports.
Autologous HCT
Several investigators used high-dose therapy and auto-
HCT consolidation in BPDCN, with the goal of maximizing
depth and duration of responses (Table 2) [13,18,21,35].
Suzuki et al. reported outcomes of high-dose therapy fol-
lowed by auto-HCT in 6 patients; 3 died from progression,
and the remaining 3were alive and disease-free at 11, 22, and
37 months after auto-HCT, respectively [35]. On the other
hand, Reimer et al. reported relapses after auto-HCT in 3 of 4
cases at a median of 13 months [13]. Several limitations are
inherent to these retrospective reports, including lack of
centralized review to conﬁrm this rare histology, heteroge-
neity in number and types of prior chemotherapies used,
varying remission status at the time of transplantation, and
a possible publication bias toward reporting favorable
outcomes. There are no available data to suggest an optimal
conditioning regimen for auto-HCT in BPDCN (eg, total body
irradiationebased versus nonetotal body irradiation-
containing regimens). The total body irradiationebased
conditioning regimen used in the report by Reimer et al.
was associated with disease relapse in 3 of 4 patients [13]. In
the case series by Suzuki et al., 3 of 6 autografted cases were
disease-free; however, the conditioning regimens were not
speciﬁed [35].
The paucity of published literature precludes identiﬁca-
tion of a particular subset of BPDCN likely to beneﬁt from
high-dose therapy and auto-HCT. It appears, however, that
patients with chemorefractory disease and those with active
central nervous system or bone marrow involvement at timeTable 2
Selected Published Data Evaluating High-Dose Chemotherapy and Auto-HCT for BP
Author Publication
Year
n (Gender) Median Age
(Range) y
S
A
Reimer et al. [13] 2003 4* (M ¼ 4) 28.5 (23-51) C
C
Yamaguchi et al. [21] 2005 1 (male) 57 C
Suzuki et al. [35] 2006 6 (M ¼ 5) 35.5 (14-61) C
C
P
P
Dalle et al. [18] 2010 1 (female) 25 C
An et al. [43] 2012 1 (male) 18 C
d indicates not reported/not speciﬁed; M, male, BuEAM, busulfan, etoposide, cyt
CR2, second complete remission; PD, progressive disease; PR, ﬁrst partial response
* Represents compiled case reports from various publications (summarized by Rof autografting are not likely to achieve durable remissions
after auto-HCT [13]. These cases should ideally be considered
for enrollment in clinical trials. However, in the absence
of such trials, acknowledging the limitations and quality
of available data, high-dose therapy and auto-HCT could be
offered to patients with chemosensitive disease, preferably
early in the disease course.
Allogeneic HCT
Allo-HCT appears to have the most favorable data
in patients with BPDCN but is anecdotal as well [13,18,20].
Not surprisingly, most reported BPDCN cases undergoing
allo-HCT are males (Table 3) [11,13,18,20,22,28,31,36,37].
Available data suggest that patients with BPDCN achieve
long-term remissions, mostly if allografted in CR [13,18]. The
European Group for Blood and Marrow Transplantation,
recently in the largest registry study to date (n ¼ 34), re-
ported 3-year cumulative incidence of relapse, disease-free
survival (DFS), and OS rates of 32%, 33%, and 41% res-
pectively, after allo-HCT [37]. Patients included in this study
had a careful central review of their diagnosis to conﬁrm this
rare histology. Patients allografted in ﬁrst CR showed
a statistically nonsigniﬁcant trend toward better 3-year DFS
(36%) and OS (52%) compared with patients who underwent
transplantation duringmore advanced disease (DFS, 26%; OS,
29%). No relapses were seen in any patients after 27 months,
suggesting a possibility of cure with allo-HCT. It is, however,
important to recognize that no robust evidence of a potent
and clinically relevant graft-versus-BPDCN effect is available.
None of the reports has examined the rates of relapse in
patients developing graft-versus-host disease compared
with those without graft-versus-host disease, and no data
are available to determine if post allo-HCT relapses are
responsive to donor lymphocyte infusions.
Reduced-intensity conditioning (RIC) regimens could in
theory expand the applicability of allo-HCT to BPDCN
patients with advanced age and at a higher risk of associated
comorbidities, which would preclude them from receiving
myeloablative regimens. For instance, Dietrich et al.
described outcomes in 4 patients, with a median age of 66
years (range, 56 to 70), who received unmanipulated
peripheral blood stem cells from unrelated donors after
a combination of ﬂudarabine, cyclophosphamide, sub-
ablative doses of busulfan with or without antithymocyte
globulin, or ﬂudarabine plus treosulfan [20]. None of these
patients died from transplantation-related toxicities, and 2
were alive in CR at 16þ and 57þ months after allografting
(Table 3) [20]. These ﬁndings demonstrate feasibility of RIC
regimens in elderly patients. It is important to point out,DCN
tatus at
uto-HCT
Regimen Outcomes
R1 ¼ 3
R2 ¼ 1
CY-TBIVP-16 Alive in CR ¼ 1
Dead ¼ 3 (all from relapsed disease)
R1 ¼ 1 CY-TBI-VP-16 Alive in CR at 20 mo
R1 ¼ 2
R2 ¼ 1
R1 ¼ 1
D ¼ 2
d Median survival 13.5 mo (range, 6-37)
R2 ¼ 1 d Alive in CR at 38 mo
R1 BuEAM Alive in CR at 31.2 mo
arabine, melphalan; CY, cyclophosphamide; CR1, ﬁrst complete remission;
; TBI, total body irradiation; VP-16, etoposide.
eimer et al. [13]).
Table 3
Selected Published Data Evaluating High-Dose Chemotherapy and Allo-HCT for BPCDN
Author Publication
Year
n (Gender) Median Age
(Range) y
Disease
Status at
Allo-HCT
Donor
Source
Cell
Source
Regimen Outcomes
Reimer
et al. [13]
2003 7* (M ¼ 5) 28 (6-35) CR1 ¼ 4
CR2 ¼ 2
CR3 ¼ 1
d BM ¼ 6
PBSC ¼ 1
Various Alive in CR ¼ 3 (at 76þ, 98þ,
and 115þ mo)
Rel/PD ¼ 2 (1 died from sepsis,
1 alive at 12 mo)
Dead in CR ¼ 2 (1 from ARDS
and 1 therapy-related)
Male et al. [22] 2010 1 (male) 50 CR ¼ 1 MRD PBSC d Alive in CR (at 18 mo)
Tsagarakis
et al. [11]
2010 5 (gender NS) d CR1 ¼ 5 d d d OS ¼ 60%
Median follow-up 15 mo
(6.6-23.4)
Dalle et al. [18] 2010 9 (M ¼ 8) 38 (25-67) d d d d Median OS 21 mo (12-77)
Mitteldorf
et al. [24]
2010 1 (male) 36 PD d BM FLU-BU-CY Achieved CR but died from
PD at 7 mo
Dietrich
et al. [20]
2011 4 (M ¼ 3) 66 (56-70) CR1 ¼ 1
CR2 ¼ 1
PR4 ¼ 1
Untreated
relapse ¼ 1
WMUD ¼ 2
PMUD ¼ 1
MMUD ¼ 1
PBSC FLU-CY-BU-
ATGy ¼ 3
Alive in CR ¼ 2 (at 16þ and
57þ mo)
Alive with relapsed disease ¼ 1
(at 20þ mo)
Dead ¼ 1 (in PD)
Lucioni et al. [17] 2011 4 (M ¼ 4) 49 (19-64) PD ¼ 2
Two as initial
therapy
d d d Two achieved CR, 3 died, 1 alive
with disease at 72 mo
Dohm et al. [27] 2011 1 (male) 32 CR2 MUD d FLU-BU-CY Relapsed at 7 mo, died
at 66 mo
Ham et al. [28] 2012 1 (male) 26 CR ¼ 1 MUD ¼ 1 PBSC CY-TBI-ATGz Alive in CR (at 2 y)
Pagano et al. [36] 2012 6 (gender NS) d CR ¼ 3
PR ¼ 1
PD ¼ 1
d d d Median OS ¼ 22.7 mo
(range, 12 to 32.9)
Alive in CR ¼ 2 (at 16 and
19 mo)
Dead ¼ 4 (1 from bleeding,
1 from GVHD, 2 from PD)
Borchiellini
et al. [42]
2012 1 (female) 60 d d BM d Alive in CR at 40 mo
Gambichler [33] 2012 1 (male) 15 CR1 MRD d d
Piccin et al. [31] 2012 1 (female) 33 d MUD ¼ 1 d CY-TBI-ATGx Died at day þ120 post-allograft
from organ failure
Roos-Weil
et al. [37]
2012 34 (M ¼ 21) 41 (10-70) CR1 ¼ 19
>CR1 ¼ 15
MRD ¼ 11
MUD ¼ 23
BM ¼ 19
PBSC ¼ 9
Cord blood ¼ 6
MA ¼ 25
RIC ¼ 9
Three-year DFS and OS 33% and
41%, respectively
d indicates not reported; M, male; BM, bone marrow cells; ARDS, adult respiratory distress syndrome; BU, busulfan; CY, cyclophosphamide; FLU, ﬂudarabine;
GVHD, graft-versus-host disease; MA, myeloablative; MMUD, mismatched-unrelated donor; MRD, matched-related donor; MUD, matched unrelated donor; NS,
not speciﬁed; PBSC, peripheral blood stem cells; PD, progressive disease; PMUD, partially matched unrelated donor; Rel, relapse; TBI, total body irradiation;
WMUD, well-matched unrelated donor.
* Represents compiled case reports from various publications (summarized by Reimer et al. [13]).
y Fludarabine 125 mg/m2, cyclophosphamide 120 mg/kg, busulfan 12 mg/kg orally, ATG 30 mg/kg.
z Dosage and frequency not reported.
x TBI 12 Gy, cyclophosphamide 120 mg/kg, ATG dose not speciﬁed.
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HCT in the European Group for Blood and Marrow Trans-
plantation study survived disease-free posttransplantation,
whereas the DFS of patients undergoing myeloablative allo-
HCT reached a plateau at 40% [37].
The absence of data regarding the presence (or lack
thereof) of a clinically relevant graft-versus-BPDCN effect
limits our ability to recommend RIC regimens for all allo-HCT
candidates. RIC regimens should probably be considered for
patients who are not ﬁt to undergo myeloablative allo-HCT
due to advanced age or medical comorbidities as previously
noted. Collaborative prospective clinical trials are certainly
needed to better deﬁne the role of allo-HCT in BPDCN.
DISCUSSION
This review highlights the remarkable paucity of data on
the biology of BPDCN and its optimal therapy. It is possible
that this disease is under diagnosed and under reported.
In cases where skin manifestations predominate the clin-
ical presentation, a focused dermatological evaluation mayinadvertently miss the hematological ﬁndings associated
with BPDCN. Accordingly, BPDCN should be considered in
the differential diagnosis of atypical skin rashes that are
refractory to conventional therapies. These include entities
such as lichen planus, systemic lupus erythematosus, psori-
asis, and others, especially when present in elder men
[23,38]. Conversely, in leukemic cases, BPDCN is likely to
be misdiagnosed as leukemia cutis [15,39]. As a matter
of fact, differentiating BPDCN from leukemia cutis could pose
a serious diagnostic challenge. Maraﬁoti et al. showed that
these could be distinguished apart by differential expression
(more abundant in BPDCN) of signaling molecules, namely
CD2AP or transcription factors such as ICSBP/IRF8 [15].
BPDCN’s clinical presentation may also mimic some lym-
phoproliferative disorders, suggesting it should be incorpo-
rated in the differential diagnosis of patients presenting with
lymphadenopathy and organomegaly, especially if associ-
ated with dermatological ﬁndings [15].
Prospective clinical trials aimed at maximizing clinical
responses to frontline therapy are needed. In the interim, it
M.A. Kharfan-Dabaja et al. / Biol Blood Marrow Transplant 19 (2013) 1006e1012 1011appears logical to offer these patients intensive induction
programs using acute lymphoblastic leukemiaelike regi-
mens such as hyper-CVAD [19] or AML-like therapies based
on limited published evidence [13,20].
BPDCN patients should be referred for an allo-HCT eval-
uation as soon as possible to determine their candidacy for
the procedure and to initiate donor identiﬁcation in eligible
cases. If a suitable human leukocyte antigenecompatible
donor is identiﬁed, allo-HCT should be considered in pati-
ents in ﬁrst CR, which appears to be a prerequisite for long-
term durable remissions. Auto-HCT could be offered in the
setting of chemosensitive disease, preferably early in the
disease course if a suitable donor is not available. In our
opinion, this represents an important treatment algorithm
to consider due to relatively short-lived remissions after
frontline therapies and because effective second-line thera-
pies remain elusive.
It is important to recognize the possibility of inherent
selection bias while interpreting the beneﬁcial role of
allo-HCT in BPDCN. For instance, it is probable that only
younger patients (age bias) attaining a CR eventually
received an allo-HCT. By deﬁnition, this younger patient
group with chemosensitive disease is already a better pop-
ulation from a biological standpoint. Hence, allo-HCT may
appear superior just by virtue of patient selection. Moreover,
most available information on management of BPDCN
is derived from retrospective case reports and single-
institution experiences and as such, suffers from several
limitations. First, no prognostic models are available to tailor
therapy to individual cases. Second, no prospective data exist
to deﬁne optimal frontline combination chemotherapy
regimen(s). Third, it is not known which subgroup of
patients (if any) is more likely to do well (or not) with
aggressive chemotherapy programs. Fourth, optimal con-
solidation modality of patients in ﬁrst remission (mainte-
nance chemotherapy versus auto-HCT versus allo-HCT) is not
known. Fifth, timing and decision to offer either an autograft
or allograft to any given patient (in ﬁrst or subsequent
remissions) remain largely factors of physician preference.
FUTURE DIRECTIONS
Moving forward, concerted efforts are required to
improve our understanding of the biology of this aggressive
malignancy and to deﬁne an evidence-based treatment
algorithm. Establishment of large, national and/or interna-
tional tumor registries could prove invaluable in elucidating
the natural history of BPDCN and to further identify prog-
nostic markers. Cooperative group efforts are needed to
develop prospective trials aimed at deﬁning the most effec-
tive therapeutic strategy for this disease. Although only
a randomized study can clarify the role and timing of auto-
HCT versus allo-HCT for BPDCN, it is unlikely that a large,
adequately powered prospective study in this rare disorder
would ever be feasible.
Moreover, studies to deﬁne the gene expression proﬁle in
BPDCN might identify targeted therapeutic approaches.
Recently, Pagano et al. described FLT3-internal tandem
duplications in a small subset of BPDCN cases [36]; this
observation, if conﬁrmed by others, could provide the basis
for further understanding the role of commercially available
FLT3 inhibitors in BPDCN. Additionally, a xenograft mouse
model of human BPDCN has shown that lenalidomide results
in tumor reductions, along with signiﬁcantly augmented
levels of active caspase-3, consistent with potential in vivo
proapoptotic and cytotoxic effects [40]. Lenalidomide couldbe potentially explored in the setting of relapsed disease
or as a maintenance approach after ﬁrst CR. Surface CD22
expression is not uncommon in dendritic cells and BPDCN
[41]; accordingly, epratuzumab might play a role in this
disease. Similarly, some cases of BPDCN express CD33 on the
cell surface, identifying a possible role for gemtuzumab
ozogamicin provided it becomes commercially available in
the future. Future progress in the treatment of BPDCN hinges
on better understanding the pathogenesis of this disease and
developing novel therapeutic modalities.ACKNOWLEDGMENTS
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